Even though we could not affect AD-related amyloid pathology by manipulation of the VEGF-C pathway, it is possible that this in different disease models or when combining VEGF-C with other compounds affecting LVs, such as Piezo1 agonists52, or known disease-modifying treatments, could result in translationally significant outcomes. This evidence concerns the gene VEGFC and Alzheimer disease.